46,564 Shares in Genmab A/S Sponsored ADR $GMAB Acquired by Diversify Wealth Management LLC

Diversify Wealth Management LLC acquired a new stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB) during the first quarter, Holdings Channel.com reports. The institutional investor acquired 46,564 shares of the company’s stock, valued at approximately $1,216,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Personal CFO Solutions LLC lifted its stake in shares of Genmab A/S by 3.7% during the first quarter. Personal CFO Solutions LLC now owns 10,866 shares of the company’s stock valued at $292,000 after acquiring an additional 386 shares during the period. Founders Capital Management increased its position in Genmab A/S by 40.0% in the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares during the period. Parallel Advisors LLC increased its position in Genmab A/S by 11.3% in the third quarter. Parallel Advisors LLC now owns 4,139 shares of the company’s stock worth $127,000 after purchasing an additional 419 shares during the period. CWM LLC raised its holdings in Genmab A/S by 18.8% during the 4th quarter. CWM LLC now owns 2,739 shares of the company’s stock worth $84,000 after purchasing an additional 433 shares during the last quarter. Finally, Osaic Holdings Inc. raised its holdings in Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on GMAB. BNP Paribas Exane raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 22nd. HC Wainwright boosted their price target on shares of Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, July 2nd. Wolfe Research began coverage on shares of Genmab A/S in a report on Friday, March 27th. They issued an “outperform” rating and a $32.00 price objective on the stock. Truist Financial assumed coverage on shares of Genmab A/S in a research note on Wednesday, May 27th. They issued a “buy” rating and a $40.00 price objective on the stock. Finally, The Goldman Sachs Group raised shares of Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Genmab A/S has an average rating of “Moderate Buy” and a consensus target price of $38.21.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB opened at $29.08 on Thursday. The firm’s 50 day simple moving average is $26.53 and its 200 day simple moving average is $28.45. Genmab A/S Sponsored ADR has a fifty-two week low of $21.00 and a fifty-two week high of $35.43. The company has a market capitalization of $18.13 billion, a price-to-earnings ratio of 22.03, a P/E/G ratio of 1.82 and a beta of 0.84. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.18 and a quick ratio of 2.17.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.